Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A pharmaceutical composition for treating cerebrovascular diseases

A technology for cerebrovascular disease and composition, applied in the field of medicine, can solve problems such as limited value

Active Publication Date: 2015-05-06
KPC PHARM INC
View PDF3 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Most stroke drugs developed with a single antithrombotic and brain protection mechanism failed to pass the clinical trial verification. From this, the medical community realized that due to the complexity of the mechanism of cerebral ischemia-reperfusion injury, the single mechanism of stroke drugs The value is relatively limited, and research and development should seek more drugs with a "multi-target" mechanism of action

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A pharmaceutical composition for treating cerebrovascular diseases
  • A pharmaceutical composition for treating cerebrovascular diseases
  • A pharmaceutical composition for treating cerebrovascular diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0030] Example 1, the effect of the combination of stilbeneside on cerebral ischemia-reperfusion injury in rats

[0031] 1 drug

[0032] 1.1 Test drug preparation

[0033] Take 6ml of water for injection, heat to 80°C, add 2g of hydroxypropyl-β-cyclodextrin, stir to dissolve, add 150mg of tristilbene, polydatin, tristilbene derivatives and tristilbene respectively Stir the composition to dissolve, add 90mg of sodium chloride and stir to dissolve, finally add water for injection to 10ml, measure the pH value of the semi-finished product (5.0-6.0), and obtain a 15mg / ml solution, and then dilute in turn to obtain a 3.75mg / ml solution for later use.

[0034] Positive control drug: Edaravone injection, source: Nanjing Xiansheng Dongyuan Pharmaceutical Co., Ltd., batch number: 80-101207

[0035] Specifications: 5ml: 10mg, traits: colorless or almost colorless clear liquid, ready for use.

[0036] 1.2 Reagents

[0037] Red tetrazolium (TTC), China Pharmaceutical Group Shanghai Ch...

Embodiment 2

[0072] Example 2: Protective effect of tristilbene glycoside composition on nerve cell damage caused by hypoxia and glucose deficiency

[0073] 1 Experimental materials

[0074] 1.1 Test sample

[0075] Preparation: After weighing an appropriate amount of tristilbene glycoside composition, add 0.01M PBS to the required volume to obtain a high-dose test product (1mg / ml); afterward, filter and sterilize through a 0.2μm filter, and use PBS in a certain proportion for corresponding Diluted to obtain each dose of the test article.

[0076] 1.2 Positive control substance 1

[0077] Name: Nimodipine

[0078] Source: Sigma

[0079] Batch number: SLBB1165V

[0080] Appearance: yellow powder

[0081] Preparation: Weigh an appropriate amount of sample and add DMSO to the required volume (3mg / ml); then filter and sterilize through a 0.2μm filter, and dilute with PBS in a certain proportion to obtain the required dose of the test product.

[0082] 1.3 Negative control substance

[...

Embodiment 3

[0120] Example 3: Study on the Maximum Tolerable Dose of Trizaperoside Composition in Mice

[0121] 1 Experimental materials

[0122] 1.1 Test sample

[0123] Preparation: Take about 30ml of water for injection, heat it to 80°C, add 10g of hydroxypropyl-β-cyclodextrin, stir to dissolve, then add 3g of tristilbeside No. 1 composition, stir to dissolve, then add 0.45g Sodium chloride is stirred and dissolved, and finally water for injection is added to make the finished product 50ml. After the pH value (5.0-6.0) of the semi-finished product is measured and the content is qualified, it is finely filtered until it is clear and ready for use.

[0124] 1.2 Negative control

[0125] Name: Hydroxypropyl-β-cyclodextrin

[0126] Source: Kunming Pharmaceutical Group Co., Ltd.

[0127] Preparation: Take about 30ml of water for injection, heat it to 80°C, add 10g of hydroxypropyl-β-cyclodextrin, stir to dissolve, then add 0.45g of sodium chloride and stir to dissolve, and finally add w...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the field of medicines and discloses a pharmaceutical composition and uses thereof. The composition comprises piceatannol 3'-O-glucoside, polydatin and a piceatannol 3'-O-glucoside derivative. Research found that the composition significantly improves the area of cerebral infarction and neurological functions after ischemia-reperfusion, fundamentally improves various damages caused by ischemia for patients with cerebrovascular diseases, has excellent treating functions for cerebrovascular diseases, and has a good clinical application prospect.

Description

technical field [0001] The invention relates to the field of medicine, in particular to a pharmaceutical composition for treating cerebrovascular diseases. Background technique [0002] Cerebral ischemia is equivalent to "stroke" and "stroke" in traditional Chinese medicine. It is clinically divided into transient and persistent cerebral ischemic attacks. The latter includes cerebral thrombosis, cerebral embolism, and vasospasm. Cerebral ischemia can lead to neuronal damage and neurological dysfunction. The neuron damage includes acute neuron necrosis and delayed neuron apoptosis. . In my country, the morbidity, disability and mortality of stroke, including cerebral infarction, remain high. [0003] The current treatment of cerebral ischemia mainly includes restoring cerebral blood flow, protecting neurons, and promoting the recovery of brain function. Antithrombotic and brain protection are the two main directions of drug development for the treatment of cerebral ischemi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7034A61P9/10A61P9/00
Inventor 龚云麒陈锦锌方芳周勇军
Owner KPC PHARM INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com